Prostate Cancer Archives - Cancer Therapy Advisor

Daniel J. George, MD, a lead investigator on the HERO study, discusses the implications of relugolix’s approval for advanced prostate cancer.

First GnRH Receptor Antagonist Enters Advanced Prostate Cancer Treatment Portfolio

By

January 20, 2021

Daniel J. George, MD, a lead investigator on the HERO study, discusses the implications of relugolix’s approval for advanced prostate cancer.

Prostate Cancer

Black Men Report More Regret Over Prostate Cancer Treatment Decisions

By

Natasha Persaud

January 15, 2021

Mistrust and concerns about masculinity are important factors that influence Black men’s experience during prostate cancer management.

Regardless of what diet patients choose, these foods should always be limited or avoided as they can cause spikes in blood sugar or contain unhealthy fats. These foods include: processed grains, fruits with added sweeteners, full-fat dairy, fried foods or foods high in trans or saturated fats, refined flour, and foods with a high glycemic load.

Prostate Cancer

Advanced, Fatal Prostate Cancer Linked to Diet

By

Jody A. Charnow

January 13, 2021

Diets that promote hyperinsulinemia and inflammation increase the likelihood of advanced or fatal prostate cancer, a new study suggests.

Prostate Cancer

Use of Commercial Genomic Testing for Prostate Cancer ‘Highly Variable’ in the United States

By

Susan Jenks

January 12, 2021

Investigators evaluated a large sample of commercially insured patients with prostate cancer to assess use of tissue-based gene expression testing.

Prostate Cancer

Overall Survival Data Added to Nubeqa Prescribing Information

By

Brian Park, PharmD

January 11, 2021

Nubeqa, an androgen receptor inhibitor, was approved for the treatment of patients with nmCRPC based on data from the placebo-controlled phase 3 ARAMIS trial.

Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.

General Oncology

Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021

By

Sean McGowan

Brian Ansay

January 8, 2021

Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.

Prostate Cancer

Orgovyx Now Available for Advanced Prostate Cancer

By

Brian Park, PharmD

January 7, 2021

Orgovyx is an oral nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist.

Prostate Cancer

Statins May Benefit Patients Receiving ADT for Relapsed Prostate Cancer

By

Jody A. Charnow

January 5, 2021

In a study, statin use was associated with a 36% decreased risk for death among men initiating androgen deprivation therapy for recurrent prostate cancer following primary or salvage radiation therapy.

Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.

Prostate Cancer

Optimal Sequencing of Therapy Identified for Prostate Cancer

By

Christina Bennett, MS

December 17, 2020

Patients with prostate cancer who received androgen deprivation therapy in the adjuvant setting instead of the neoadjuvant setting had better clinical outcomes.

Prostate Cancer

Level of Experience at Radiation Facility Linked to Prostate Cancer Survival

By

Christina Bennett, MS

December 16, 2020

Treatment at a radiation facility that had a high level of experience treating patients with prostate cancer was associated with better patient survival.